Allergen-specific oral immunotherapy for peanut allergy (Q24200573)

21 October 2023

4

F Estelle R

Simons

F Estelle R Simons

1 reference

21 October 2023

Ulugbek Nurmatov

1

Ulugbek

Nurmatov

1 reference

22972130

21 October 2023

Iris Venderbosch

series ordinal

2

author given names

Iris

author last names

Venderbosch

1 reference

22972130

21 October 2023

Graham Devereux

series ordinal

3

author given names

Graham

author last names

Devereux

1 reference

22972130

Cochrane Database of Systematic Reviews

21 October 2023

language of work or name

English

0 references

publication date

12 September 2012

0 references

published in

0 references

issue

9

0 references

page(s)

CD009014

0 references

cites work

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Oral peanut immunotherapy in children with peanut anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Successful oral tolerance induction in severe peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Clinical efficacy and immune regulation with peanut oral immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

The psychosocial impact of anaphylaxis on young people and their parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Immunotherapy: The meta-analyses. What have we Learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Management of nut allergy influences quality of life and anxiety in children and their mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Impact of peanut allergy on quality of life, stress and anxiety in the family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Incidence, prevalence, and trends of general practitioner-recorded diagnosis of peanut allergy in England, 2001 to 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Allergy or tolerance in children sensitized to peanut: Prevalence and differentiation using component-resolved diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Oral immunotherapy for peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Treatment of peanut allergy with rush immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Summary of the 2008 National Institute of Allergy and Infectious Diseases-US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Sublingual immunotherapy for allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Peanut allergy: emerging concepts and approaches for an apparent epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Anaphylaxis: Recent advances in assessment and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Emergency treatment of anaphylactic reactions--guidelines for healthcare providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Peanut oral immunotherapy is not ready for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Accidental ingestions in children with peanut allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Epinephrine auto-injector use in adolescents at risk of anaphylaxis: a qualitative study in Scotland, UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

1 reference

7 January 2021

World Allergy Organization anaphylaxis guidelines: Summary

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

Successful oral desensitization for systemic peanut allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021

Oral immunotherapy for peanut allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009014.PUB2

7 January 2021